Ann Zauber, PhD

Member, Attending Biostatistician

Ann Zauber, PhD

Member, Attending Biostatistician

Pictured: Ann Zauber

Office Phone

646-888-8304

E-mail

zaubera@mskcc.org

Current Research Interests

Dr. Zauber’s primary research focus is the impact of screening, surveillance, and chemoprevention on the national burden of colorectal cancer. Her work involves population based modeling to inform health policy and randomized clinical trials. Dr. Zauber leads a multi-center group of microsimulation modelers from the NCI consortium of the Cancer Intervention and Surveillance Modeling Network (CISNET) to address specific health policy questions in colorectal cancer screening. She conducted a decision analysis to inform the United States Preventive Services Task Force (USPSTF) in their recommendations on the age to begin, age to stop, and the intervals of re-testing for colorectal cancer screening for currently recommended tests. She also conducted cost-effectiveness analyses on CT colonography and stool DNA for colorectal cancer screening in the general population for the Centers for Medicare and Medicaid Services. The Annual Report to the Nation on Cancer (2010) featured colorectal cancer. Dr. Zauber led the special section in which microsimulation modeling showed that colorectal cancer screening contributed to more than 50% of the reduction in colorectal cancer over the past 25 years and that increased screening utilization can provide for continued reductions in mortality. Dr. Zauber is also the Principal Investigator for a multi-center randomized controlled trial of screening colonoscopy compared to a program of annual testing with fecal occult blood tests (National Colonoscopy Study) and a multi Principal Investigator on the NCI PROSPR consortium and co-investigator on a case control study of colonoscopy screening and colorectal cancer deaths. In addition she continues her assessment of risk factors for adenoma recurrence in the Adenoma Prevention with Celecoxib trial. She also has led the long term follow-up of the National Polyp Study demonstrating a large reduction in colorectal cancer with removal of adenomatous polyps.

Education

Johns Hopkins University

Publications

Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Nov 4; 149(9):659-69. Epub 2008 Oct 6. Summary for patients in: Ann Intern Med. 2008 Nov 4; 149(9):I-44

Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst. 2010; 102(16):1238-52.

Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116(3):544-73.

Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A. Contribution of screening and survival differences to racial disparities in colorectal cancer rates.  Cancer Epidemiol Biomarkers Prev. 2012; 21(5):728-36

Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012; 366(8):687-96

Read more
  1. German PS, Hoey JR, Horky R, Levine DM, Skinner EA, West SK, Zauber AG. Symposium: Health care of the aged in four ambulatory settings with a focus on the hypertensive patient. Gerontologist 1975; 15:311.

  2. West SK, Brandon BM, Stevens AM, Zauber AG, Chase GA, Stolley PD, Rumrill RE. Drug utilization in an HMO: 1. Introduction and examples of methodology. Med Care 1977; 15:505-514.

  3. Skinner EA, German PS, Shapiro S, Chase GA, Zauber AG. Use of ambulatory health service by the near poor. Am J Pub Health 1978; 68:1195-1201.

  4. Schottenfeld D, Morgan RW, Zauber AG. Questions raised by study on cancer mortality in oil refinery workers. Journal of Occupational Medicine 1980; 2:69-70.

  5. Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980; 112:232-246.

  6. Fisher B, Montague E, Redmond C, Deutsch M, Brown GR, Zauber AG, Hanson WF, Wong A. Findings from NSABP protocol no. B-04—comparison of radical mastectomy with alternative treatments for primary breast cancer. I. Radiation compliance and its relation to treatment outcomes. Cancer 1980; 46:1-13.

  7. Miransky J, Kerner JF, Sturgeon SR, Zauber A, Strickman NA, Senie RT, Anderson R. A comparison of primary breast cancer management in small, intermediate and large community hospitals and a comprehensive cancer center. Prog Clin Biol Res 1984; 156:87-96.

  8. Kerner JF, Winn R, Robertson P, Zauber A, Bleadingheiser LJ. An MSKCC-Community hospital colorectal carcinoma audit: a cancer control project. Prog Clin Biol Res 1983; 120:79-84.

  9. Schottenfeld D, Zauber AG, Kerner JF, Warshauer ME. Recent trends in cancer survival. Trans Assoc Life Insur Med Dir Am 1986; 69:66-86.

  10. Zauber NP, Zauber AG. Hematologic data of healthy very old people. JAMA 1987; 257:2181-2184.

  11. Kerner JF, Andrews H, Zauber AG, Struening E. Geographically-Based Cancer Control: Methods for targeting and evaluating the impact of screening interventions on defined populations. J Clin Epidemiol 1988; 41:543-553.

  12. Kushner BH, Zauber AG, Tan CT. Second malignancies after childhood Hodgkin’s disease. Cancer 1988; 62:1364-1370.

  13. Winawer SJ, Zauber A, Diaz B, O’Brien M, Gottlieb LS, Sternberg SS, Waye JD, Shike M. The National Polyp Study: overview of program and preliminary report of patient and polyp characteristics. Prog Clin Biol Res 1988; 279:35-49.

  14. O’Brien MJ, Winawer SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz B, Dickersin R, Ewing S, Geller S, Dasimian D, Komorowski R, Szporn A, National Polyp Study Workgroup. The National Polyp Study: Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98:371-379.

  15. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. Vasectomy and the risk of prostate cancer. Am J Epidemiol 1990; 132:1051-5.

  16. Winawer SJ, O’Brien MJ, Waye JD, Kronborg O, Bond J, Fruhmorgen P, Sobin LH, Burt R, Zauber A, Morson B, WHO Collaborating Center for the Prevention of Colorectal Cancer. Risk and surveillance of individuals with colorectal polyps. WHO Bulletin 1990; 68(6):789-795. Reprint No. 5136.

  17. Winawer SJ, Zauber AG, Stewart E, O’Brien MJ. The natural history of colorectal cancer: Opportunities for intervention. Cancer 1991; 67:1143-1149.

  18. Fleisher M, Winawer SJ, Zauber AG, Smith C, Schwartz MK, National—Polyp Study Workgroup. Accuracy of fecal occult blood test interpretation. Ann Int Med, 1991; 114:875-6.

  19. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S. A Hypothesis: NSAIDs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83:355-58.

  20. Palmer JR, Rosenberg L, Clarke EA, Stolley PD, Warshauer ME, Zauber AG, Shapiro S. Breast Cancer and Cigarette Smoking: A Hypothesis. Am J Epidemiol 1991; 134:1-13.

  21. Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Urmacher C, Brennan M. Preoperative staging of esophageal cancer: comparison of endoscopic US and dynamic CT. Radiol 1991; 181:419-425.

  22. Botet JF, Lightdale CJ, Zauber AG, Gerdes H, Winawer SJ, Urmacher C, Brennan M. Preoperative staging of gastric cancer: comparison of endoscopic US and dynamic CT. Radiol 1991; 181:426-432.

  23. Mandelblatt J, Andrews H, Kerner J, Zauber A, Burnett W. Determinants of late stage diagnosis of breast and cervical cancer: the impact of age, race, social class and hospital type. Am J Pub Health 1991; 81:646-649.

  24. Kaufman DW, Palmer JR, de Mouzon J, Rosenberg L, Stolley PD, Warshauer E, Zauber AG, Shapiro S. Estrogen replacement therapy and the risk of breast cancer: results from the case-control surveillance study. Am J Epidemiol 1991; 134:1375-85.

  25. Johannes CB, Kaufman DW, Rosenberg L, Palmer JR, Stolley PD, Lewis Jr. JL, Zauber AG, Warshauer ME, Shapiro S. Side of origin of epithelial ovarian cancer. Br Med J 1992; 304:27-28.

  26. Zauber NP, Zauber AG, Gordon FJ, Tillis AC, Leeds HC, Berman E, Kudryk AB. Iron supplementation after femoral head replacement for patients with normal iron stores. JAMA 1992; 267:525-527.

  27. Dusenbury L, Kerner J, Baker E, Botvin G, James-Ortoz S, Zauber A. Predictors of smoking prevalence among New York latino youth. Am J Pub Health 1992; 82:55-58.

  28. Robinson E, Zauber A, Fuks Z, Strong E. Clinical characteristics of patients with epidermoid carcinoma of the upper aerodigestive tract who develop second malignant tumors. Cancer Detect Pre 1992; 16(5-6):297-303.

  29. Winawer SJ, Zauber AG, O’Brien MJ, Gottlieb LS, Sternberg SS, Stewart ET, Bond JH, Schapiro M, Panish JF, Waye JD, Kurtz RC, Shike M, Ho MN, The National Polyp Study Workgroup. Design, methods and characteristics of patients with newly diagnosed polyps. Cancer 1992; 70:1236-1245.

  30. O’Brien MJ, O’Keane JC, Zauber AG, Gottlieb LS, Winawer SJ. Precursors of colorectal carcinoma: biopsy and biological markers. Cancer 1992; 70:1317-27.

  31. Palmer JR, Rosenberg L, Strom BL, Harlap S, Zauber AG, Warshauer ME, Shapiro S. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 1992; 3:547-54.

  32. Winawer SJ, Zauber AG, O’Brien MJ, Ho MN, Gottlieb L, Sternberg SS, Waye JD, Bond J, Schapiro M, Stewart ET, Panish J, Ackroyd F, Kurtz RC, Shike M, National Polyp Study Workgroup. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 1993; 328:901-6.

  33. Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF, Ackroyd F, Shike M, Kurtz RC, Hornsby-Lewis L, Gerdes H, Stewart ET, National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993; 329:1977-81.

  34. Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, Stewart ET, Bond JH, Schapiro M, Panish JF, Waye JD, Kurtz RC, Shike M, National Polyp Study Workgroup. The National Polyp Study. Eur J Cancer Prev 1993; 2Suppl:83-87.

  35. Andrews H, Kerner JF, Zauber AG, Mandelblatt J, Pittman J, Struening E. Using census and mortality data to target small areas for breast, colorectal, and cervical cancer screening. Am J Publ Hlth 1994; 84:56-61.

  36. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL, Harlap S, Shapiro S. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 1994; 139:654-61.

  37. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Strom BL, Harlap S, Shapiro S. The relation of vasectomy to the risk of cancer. Am J Epidemiol 1994; 140:1-8.

  38. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Strom BL, Harlap S, Shapiro S. The relation of benzodiazepine use to the risk of selected cancers: Breast, large bowel, malignant melanoma, lung, endometrium, ovary, non-Hodgkin’s lymphoma, testis, Hodgkin’s disease, thyroid and liver. Am J Epidemiol 1995; 141:1153-1160.

  39. Boivin J-F, Hutchinson CB, Zauber AG, Bernstein L, Davis FG, Michel RP, Zanke B , Tan CTC, Mauch P, Ultmann JE. The incidence of second cancers in patients treated for Hodgkin’s disease. J Natl Cancer Inst 1995; 87:732-741.

  40. Palmer JR, Rosenberg L, Harlap S, Strom BL, Warshauer ME, Zauber AG, Shapiro S. Adult height and risk of breast cancer among US black women. Am J Epidemiol 1995; 141(9):845-849.

  41. Palmer JR, Rosenberg L, Rao RS, Strom BL, Warshauer ME, Harlap S, Zauber A, Shapiro S. Oral contraceptive use and breast cancer risk among African-American Women. Cancer Causes Control 1995; 6:321-331.

  42. Winawer SJ, Zauber AG, Gerdes H, O’Brien MJ, Gottlieb LS, Sternberg SS, Bond JH, Waye JD, Schapiro M, Panish JF, Kurtz RC, Shike M, Ackroyd FW, Stewart ET, Bishop DT, National Polyp Study Workgroup. Risk of colorectal cancer in families of people with adenomatous polyps. N Engl J Med 1996; 334:82-87.

  43. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Strom BL, Harlap S, Shapiro S. A case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 1996; 143:25-37.

  44. Zhang Y, Rosenberg L, Colton T, Cupples LA, Palmer JR, Strom BL, Zauber AG, Warshauer ME, Harlap S, Shapiro S. Adult height and risk of breast cancer among white women in a case-control study. Am J Epidemiology 1996; 143:1123-1128.

  45. Koblin BA, Hessol NA, Zauber AG, Taylor PE, Buchbinder SP, Katz MH, Stevens CE. Increased incidence of cancer among homosexual men, New York City and San Francisco, 1978–1990. Am J Epidemiol 1996; 144:916-23.

  46. Palmer JR, Rosenberg L, Rao RS, Zauber AG, Strom BL, Warshauer ME, Stolley, PD, Shapiro S. Induced and spontaneous abortion in relation to risk of breast cancer (United States). Cancer Causes and Control 1997; 8:841-849.

  47. Rosenberg L, Rao RS, Palmer JR, Strom Bl, Zauber A, Warshauer ME, Shapiro S. Transitional cell cancer of the urinary tract and renal cell cancer in relation to acetaminophen use (United States). Cancer Causes Control 1998; 9:83-88.

  48. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME, Shaprio S. Calcium channel blockers and the risk of cancer. JAMA 1998; 279:1000-1004.

  49. Harlap S, Zauber AG, Pollack DM, Tang J, Arena AE, Sternfels P, Borgen P, Norton L. Survival of premenopausal women with breast carcinoma: effects of menstrual timing of surgery. Cancer 1998; 83:76-88.

  50. Olson SH, Zauber AG, Tang J, Harlap S. Relation of time since last birth and parity to survival of young women with breast cancer. Epidemiology 1998; 9:669-671.

  51. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Stolley PD, Zauber AG, Shapiro S. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999; 2:72-76.

  52. Kelly JP, Rosenberg L, Palmer JR, Rao RS, Strom BL, Stolley PD, Zauber AG, Shapiro S. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. American Journal of Epidemiology 1999; 150:861-868.

  53. Ostroff J, Garland J, Moadel A, Fleshner N, Hay J, Cramer L, Zauber A, Trambert R, O’Sullivan ME, Russo P. Cigarette smoking patterns in patients after treatment of bladder cancer. J Cancer Educ 2000; 15:86-90.

  54. Coogan PF, Rosenberg L, Palmer JR, Strom, BL, Zauber AG, Stolley PD, Shapiro S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiology, Biomarkers and Prevention 2000; 9:119-123.

  55. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Stolley PD, Zauber AG, Shapiro S. Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines. Cancer Causes Control 2000; 11:839-845.

  56. Coogan PF, Rosenberg L, Louik C, Zauber AG, Stolley PD, Strom BL, Shapiro S. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes and Control 2000; 11:249-255.

  57. Winawer SJ, Stewart ET, Zauber AG, Bond JH, Ansel H, Waye JD, Hall D, Hamlin JA, Schapiro M, O’Brien MJ, Sternberg SS, Gottlieb LS, Hogan WJ, Khilani M, Ackroyd FW, Panish JF, Kussin L, Edelman M. A comparison of colonoscopy and double-contrast barium enema for surveillance after polypectomy. N Engl J Med 2000; 342:1766-72.

  58. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD, Shapiro S. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiology Biomarkers & Prevention 2000; 9:933-937.

  59. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. Phenolphthalein laxatives and risk of cancer. J Natl Cancer Inst 2000; 92:1943-1944.

  60. Zauber NP, Sabbath-Solitare M, Marotta SP, Zauber AG, Bishop DT. Molecular changes in the Ki-ras and APC genes in colorectal adenomas and carcinomas arising in the same patient. J of Pathology 2001; 193:303-309.

  61. Coogan PF, Rosenberg L, Palmer J, Strom BL, Zauber AG, Shapiro S. The relationship of statin use to the risk of breast and prostate cancer. Epidemiology 2002; 13:262-267.

  62. Blackman JA, Coogan PF, Rosenberg L, Strom BL, Zauber AG, Palmer JR, Langenberg P, Shapiro S. Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 2002; 11:61-7.

  63. Loeve F, Boer R, Zauber AG, van Ballegooijen M, van Oortmarssen GJ, Winawer SJ, Habbema JD. National Polyp Study data: evidence for regression of adenomas. Int J Cancer 2004; 111:633-9.

  64. O’Brien MJ, Winawer SJ, Zauber AG, Bushey MT, Sternberg SS, Gottlieb LS, Bond JH, Waye JD, Schapiro M. Flat Adenomas in the National Polyp Study: Is There Increased Risk for High-Grade Dysplasia Initially or During Surveillance? Clinical Gastroenterology and Hepatology 2004; 2:905-911.

  65. Zauber P, Sabbath-Solitare M, Marotta S, Zauber A, Bishop T. Comparative molecular pathology of sporadic hyperplastic polyps and neoplastic lesions from the same individual. J Clin Pathol 2004: 57:1084-1088.

  66. 66.Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-80.

  67. Zauber NP, Sabbath-Solitare M, Marotta S, Zauber AG, Foulkes W, Chan M, Turner F, Bishop DT. Clinical and genetic findings in an Ashkenazi Jewish population with colorectal neoplasms. Cancer 2005; 104:719-29.

  68. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O’Brien MJ, Levin B, Smith RA, Lieberman DA, Burt RW, Levin TR, Bond JH, Brooks D, Byers T, Hyman N, Kirk L, Thorson A, Simmang C, Johnson D, Rex DK. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer: and the American Cancer Society. Joint publication in Gastroenterology 2006:130:1872-85 and CA Cancer J Clin 2006; 56:143-59.

  69. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim KM, Tang J, Rosenstein RB., Janet Wittes, Ph.D., Donald Corle, M.S., Timothy M. Hess, M.S., G. Mabel Woloj, Ph.D., William F. Anderson, M.D., M.P.H., Jaye L. Viner, M.D., M.P.H., Donya Bagheri, M.S., D.A.B.T., Gary B. Gordon, M.D., Ph.D., Frederic Boisserie, John Burn, M.D., Daniel C. Chung, M.D., Thomas Dewar, M.D., T. Raymond Foley, M.D., Neville Hoffman, M.D., Finlay Macrae, M.D., Ronald E. Pruitt, M.D., John R. Saltzman, M.D., Bruce Salzberg, M.D., Thomas Sylwestrowicz, M.D., Ernest T. Hawk, M.D., M.P.H. for the Adenoma Prevention with Celecoxib (APC) Study Investigators. Prevention of Sporadic Colorectal Adenomas with Celecoxib: Results of a Randomized Trial. N Engl J Med 2006; 355:873-84.

  70. Arber N, Eagle C, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885-95.

  71. Solomon SD, Pfeffer MA, McMurray JJV, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli M, Arber N, Wittes J. Effect of celecoxib on cardiovascular events and blood pressure in two trials for prevention of colorectal adenoma. Circulation 2006; 114:1028-1035.

  72. * Vogelaar I, van Ballegooijen M, Schrag D, Boer R, Winawer SJ, Habbema JDF, Zauber AG. How much can current interventions reduce colorectal cancer mortality in the US? Mortality projections for scenarios of risk factor modification, screening and treatment. Cancer 2006; 107:1624-33.

  73. Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer.

    Olson SH, Orlow I, Simon J, Tommasi D, Roy P, Bayuga S, Ludwig E, Zauber AG, Kurtz RC. Cancer Detect Prev 2007; 31(5):345-51.

  74. Colonoscopy surveillance after polypectomy and colorectal cancer resection.

    Brooks DD, Winawer SJ, Rex DK, Zauber AG, Kahi CJ, Smith RA, Levin B, Wender R; U.S. Multi-Society Task Force on Colorectal Cancer; American Cancer Society. Am Fam Physician. 2008 Apr 1; 77(7):995-1002.

  75. Cho NL, Redston M, Zauber AG, Carothers AM, Hornick J, Wilton A, Sontag S, Nishioka N, Giardiello FM, Saltzman JR, Gostout C, Eagle CJ, Hawk ET, Bertagnolli MM. Aberrant crypt foci in the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila Pa). 2008 Jun; 1(1):21-31.

  76. Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization.

    Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, Grossman DC. Med Care. 2008 Sep; 46(9 Suppl 1):S91-6.

  77. Zauber AG, Levin TR, Jaffe CC, Galen BA, Ransohoff DF, Brown ML. Implications of new colorectal cancer screening technologies for primary care practice. Med Care. 2008 Sep; 46 (9 Suppl 1):S138-46.

  78. Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force.

    Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Ann Intern Med. 2008 Nov 4; 149(9):659-69. Epub 2008 Oct 6. Summary for patients in: .

  79. Variants in hormone biosynthesis genes and risk of endometrial cancer.

    Olson SH, Orlow I, Bayuga S, Sima C, Bandera EV, Pulick K, Faulkner S, Tommasi D, Egan D, Roy P, Wilcox H, Asya A, Modica I, Asad H, Soslow R, Zauber AG. Cancer Causes Control. 2008; 19(9):955-63.

  80. At what costs will screening with CT colonography be competitive? A cost-effectiveness approach.

    Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD Int J Cancer. 2009; 124(5):1161-8.

  81. Chan AT, Zauber AG, Hsu M, Breazna A, Hunter DF, Rosenstein RB, Eagle CJ, Hawk EJ, Bertagnolli MM. Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma. Gastroenterology 2009; 136(7):2127-2136.

  82. Martinez ME, Baron JA, Lieberman DA, Schatzkin A, Lanza E, Winawer SJ, Zauber AG, Jian R, Ahnen DN, Bond JH, Church TR, Robertson DF, Smith-Warner, SA, Jacobs ET, Alberts DS. Greenberg ER. A pooled analysis of advanced colorectal neoplasia diagnosis after colonoscopic polypectomy. Gastroenterology 2009; 136(3):832-41. Epub 2008 Dec 9.

  83. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET; Adenoma Prevention with Celecoxib Study Investigators. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res (Phila Pa). 2009; 2(4):310-21.

  84. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Habbema JD. At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. Int J Cancer. 2009; 124(5):1161-8.

  85. Lansdorp-Vogelaar I, van Ballegooijen M, Boer R, Zauber A, Habbema JD. A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. Cancer. 2009; 115(11):2410-9.

  86. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Boer R, Wilschut J, Winawer SJ, Habbema JD. Individualizing colonoscopy screening by sex and race. Gastrointest Endosc 2009; 70(1):96-108.

  87. Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ. Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. J Natl Cancer Inst. 2009; 101(20):1412-22.

  88. Lambert R, Kudo SE, Vieth M, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, O’Brien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Zauber A, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Jass JR, Triadafilopoulos G. Pragmatic classification of superficial neoplastic colorectal lesions. Gastrointest Endosc. 2009; 70(6):1182-99.

  89. Nagula S, Ishill N, Nash C, Markowitz AJ, Schattner MA, Temple L, Weiser MR, Thaler HT, Zauber A, Gerdes H. Quality of life and symptom control after stent placement or surgical palliation of malignant colorectal obstruction. J Am Coll Surg. 2010; 210(1):45-53.

  90. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Ballegooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010; 116(3):544-73.

  91. * Bertagnolli MM, Hsu M, Hawk ET, Eagle CJ, Zauber AG; Adenoma Prevention with Celecoxib (APC) Study Investigators. Statin use and colorectal adenoma risk: results from the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila Pa). 2010; 3(5):588-96.

  92. Ma J, Liu W, Zhang L, Pan K, Zhao H, Zhou T, Winawer S, Zauber A, Classen M, You W. A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial. Eur J Gastroenterol Hepatol. 2010; 22(5):597-601.

  93. * Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Savarino JE, van Ballegooijen M, Kuntz KM, Zauber AG. Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. J Natl Cancer Inst. 2010; 102(16):1238-52.

  94. Bandera EV, Williams-King MG, Sima C, Bayuga-Miller S, Pulick K, Wilcox H, Zauber AG, Olson SH. Coffee and tea consumption and endometrial cancer risk in a population-based study in New Jersey. Cancer Causes Control. 2010; 21(9):1467-73.

  95. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med. 2010 Sep 21; 153(6):368-77.

  96. Chandran U, Bandera EV, Williams-King MG, Sima C, Bayuga S, Pulick K, Wilcox H, Zauber AG, Olson SH. Adherence to the dietary guidelines for Americans and endometrial cancer risk. Cancer Causes Control. 2010 Nov; 21(11):1895-904.

  97. van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, Boer R, Feuer EJ, Habbema JDF, Kuntz KM. Clarifying differences in natural history between models of screening: The case of colorectal cancer. Med Decis Makin 2011 July-Aug;31(4):540-9. Epub 2011 Jun 14.

  98. de Gonzalez AB, Kim KP, Landsdorp-Vogelaar I, Rutter CM, Smith-Bindman R, Yee J, Kuntz KM, van Ballegooijen M, Zauber AG, Berg CD. Radiation-related cancer risks from CT colonography screening: A risk-benefit analysis. American Journal of Roentgenology. 2011; 196(4):816-23.

  99. Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM. The Influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma. Cancer Prev Res (Phila) 2012; 5:61-72.

  100. Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res (Phila). 2011; 4(8):1172-80.

  101. Vanness DJ, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Gareen IF, Herman BA, Kuntz KM, Zauber AG, van Ballegooijen M, Feuer EJ, Chen MH, Johnson CD. Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. Radiology. 2011; 261(2):487-98.

  102. Jones AM, Beggs AD, Carvajal-Carmona L, Farrington S, Tenesa A, Walker M, Howarth K, Ballereau S, Hodgson SV, Zauber AG, Bertagnolli M, Midgley R, Campbell H, Kerr D, Dunlop MG, Tomlinson IP. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut. 2012; 61(2):248-54.

  103. van Ballegooijen M, Rutter CM, Knudsen AB, Zauber AG, Savarino JE, Lansdorp-Vogelaar I, Boer R, Feuer EJ, Habbema JD, Kuntz KM. Clarifying differences in natural history between models of screening: the case of colorectal cancer. Med Decis Making. 2011; 31(4):540-9. Epub 2011 June 14.

  104. * Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, Feuer EJ, Zauber AG. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Making. 2011 Jul-Aug; 31(4):530-9. Epub 2011 June 14.

  105. Berrington de González A, Kim KP, Knudsen AB, Lansdorp-Vogelaar I, Rutter CM, Smith-Bindman R, Yee J, Kuntz KM, van Ballegooijen M, Zauber AG, Berg CD. Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. AJR Am J Roentgenol. 2011; 196(4):816-23.

  106. Shike M, Schattner M, Genao A, Grant W, Burke M, Zauber AG, Russo L, Cuyjet V. Expanding colorectal cancer screening among minority women. Cancer. 2011; 117(1):70-6.

  107. Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B. The APC and PreSAP Trials: A Post Hoc Noninferiority Analysis Using a Comprehensive New Measure for Gastrointestinal Tract Injury in 2 Randomized, Double-Blind Studies Comparing Celecoxib and Placebo. Clin Ther. 2012; 34(3):569-79.

  108. Zauber AG, Winawer SJ, O’Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012; 366(8):687-96.

  109. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami H-O, van Ballegooijen M, Regula J, van Leerdam M, Stefansson T, Påhlman L, Dekker E, Hernán MA, Garborg K, Hoff G. The NordICC Study: Rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy. 2012; 44:1-8.

  110. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, van Ballegooijen M, Zauber AG, Jemal A. Contribution of screening and survival differences to racial disparities in colorectal cancer rates.  Cancer Epidemiol Biomarkers Prev. 2012; 21(5):728-36.

  111. Elkin EB, Snow JG, Shapiro E, Zauber AG, Krauskopf MS. The economic impact of a patient navigator program to increase screening colonoscopy. Cancer. 2012; May 17.

  112. Kaminski MF, Bretthauer M, Zauber AG, Kuipers EJ, Adami HO, van Ballegooijen M, Regula J, van Leerdam M, Stefansson T, Påhlman L, Dekker E, Hernán MA, Garborg K, Hoff G. The NordICC Study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy. 2012; 44(7):695-702.

  113. O’Mahony JF, van Rosmalen J, Zauber AG, van Ballegooijen M. Multicohort Models in Cost-Effectiveness Analysis: Why Aggregating Estimates over Multiple Cohorts Can Hide Useful Information. Medical Decision Making. 2013 Apr;33(3):407-14. PMCID: PMC3606654

  114. Doubeni CA, Major JM, Laiyemo AO, Schootman M, Zauber AG, Hollenbeck AR, Sinha R, Allison J. Contribution of behavioral risk factors and obesity to socioeconomic differences in colorectal cancer incidence. J Natl Cancer Inst. 2012; 104(18):1353-62.

  115. Kapidzic A, Korfage IJ, van Dam L, van Roon AH, Reijerink JC, Zauber AG, van Ballegooijen M, Kuipers EJ, van Leerdam ME. Quality of life in participants of a CRC screening program. Br J Cancer. 2012; 107(8): 1295-301.

  116. Carvajal-Carmona LG, Zauber AG, Jones AM, Howarth K, Wang J, Cheng T; APC Trial Collaborators; APPROVe Trial Collaborators; CORGI Study Collaborators; Colon Cancer Family Registry Collaborators; CGEMS Collaborators, Riddell R, Lanas A, Morton D, Bertagnolli MM, Tomlinson I. Much of the population genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas.  Gastroenterology. 2013; 144(1):53-5.

  117. Wang YC, Graubard BI, Rosenberg MA, Kuntz KM, Zauber AG, Kahle L, Schechter CB, Feuer EJ. Derivation of background mortality by smoking and obesity in cancer simulation models. Med Decis Making. 2013; 33 (2): 176-197.

  118. Khoury MJ, Lam TK, Ioannidis JP, Hartge P, Spitz MR, Buring JE, Chanock SJ, Croyle RT, Goddard KA, Ginsburg GS, Herceg Z, Hiatt RA, Hoover RN, Hunter DJ, Kramer BS, Lauer MS, Meyerhardt JA, Olopade OI, Palmer JR, Sellers TA, Seminara D, Ransohoff DF, Rebbeck TR, Tourassi G, Winn DM, Zauber A, Schully SD. Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev. 2013; 22(4):508-16.

  119. Robertson DJ, Lieberman DA, Winawer SJ, Ahnen DJ, Baron JA, Schatzkin A, Cross AJ, Zauber AG, Church TR, Lance P, Greenberg ER, Martínez ME. Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut 2014 Jun;63(6):949-56.

  120. Eldridge RC, Doubeni CA, Fletcher RH, Zauber AG, et al. Uncontrolled confounding in studies of screening effectiveness: an example of colonoscopy. Journal of Medical Screening 2013;20:198-207.

  121. Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG; APC Trial Collaborators, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clinical Cancer Research. 2013 Dec 1;19(23):6430-7. PMCID: PMC4037290

  122. Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, Doubeni CA, Zauber AG, et al. Adenoma Detection Rate and Risk of Colorectal Cancer and Death. New England Journal of Medicine 2014;370:1298-306.

  123. Van Hees F, Habbema JDF, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Annals of Internal Medicine 2014:160:7450-759.

  124. Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS. Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Annals of Internal Medicine 2014 Jul 15;161(2):104-12.

BOOKS, BOOK CHAPTERS, AND REVIEWS

  1. Schottenfeld D, Warshauer ME, Zauber AG, Meikle JG, Hart BR. A prospective study of morbidity and mortality in petroleum industry employees in the US—a preliminary report. In: Peto R, Schneiderman M, eds. Quantification of occupational cancer, Banbury Report 9. New York: Cold Spring Harbor Laboratory, 1981:247-265.

  2. Kerner JF, Winn R, Robertson P, Zauber AG, Bleadingheiser LJ. An MSKCC-community hospital colorectal carcinoma audit: A cancer control project. In: Engstrom P, Anderson P, Mortenson L, eds. Advances in cancer control research and development. New York: Alan R Liss, Inc., 1983:79-84.

  3. Miransky J, Kerner JF, Sturgeon SR, Zauber AG, Strickman N, Senie RT, Anderson R. A comparison of primary breast cancer management in small, intermediate, and large community hospitals versus a comprehensive cancer center. In: Engstrom PF, Anderson PN, Mortenson LE, eds. Advances in cancer control epidemiology and research. New York: Alan R Liss, Inc., 1984:87-96.

  4. Winawer SJ, Ritchie M, Diaz B, Gottlieb LS, Stewart ET, Zauber AG, Herbert E, Bard JH. The National Polyp Study: Aims and organization. In: Rozen F, Winawer SJ, eds. Frontiers of Gastrointestinal Research. Vol. 10: Secondary Prevention of Colorectal Cancer: An International Perspective. Basel: Karger, 1986:216-225.

  5. Winawer SJ, Zauber AG, Diaz B, O’Brien M, Gottlieb LS, Sternberg SS, Waye JD, Shike M, NPS Workgroup. The National Polyp Study: Overview of program and preliminary report of patient and polyp characteristics. Progress in Clinical and Biological Research 1988; 279: 35-49. Steele G,Jr, Burt RW, Winawer SJ, Karr JP, eds. Basic and clinical perspectives of colorectal polyps and cancer. New York: Alan R. Liss, 1988:35-49.

  6. O’Brien MJ, Winawer SJ, Zauber AG, Diaz B, Gottlieb LS, Bond J, Geenen J, Hogan W, Panish JE, Waye JD, Schapiro M, National Polyp Study Workgroup. The United States National Polyp Study. In: Hirschowitz, BI ed. Accomplishments in Oncology. Vol 3. Philadelphia: J.B. Lippincott Co., 1989; 1:211-224

  7. O’Brien MJ, O’Keane JC, Gottlieb LS, Zauber AG, Winawer SJ. Adenoma Progression to Carcinoma: Classification of Phenotypic Changes.p59-65, in Rossini FR et al (eds): Recent Progress in Colorectal Cancer: Biology and Management of High-Risk Groups. Amsterdam, Elsevier, 1992

  8. Zauber AG, Bond JH, Winawer SJ. Surveillance of patients with adenomas or cancer. In: Young GP, London. Young G, Rosen P, Levin B, eds. Prevention and Early Detection of Colorectal Cancer. London: W.B. Saunders 1996; 195-215.

  9. Zauber AG, Winawer SJ. Initial management and follow-up surveillance of patients with colorectal adenomas. Gastroenterology Clinics of North America 1997; 26:85-101. Review.

  10. DiPlacido J, Zauber A, Redd WH. Psychosocial issues in Cancer Screening In Textbook of Psycho-Oncology, Holland J, Breitbart W, Massie M, Lederberg M, Loscalzo M, McCorkle R, Jacobsen P, eds. Oxford Press: New York,1998; 161-176.

  11. Zauber AG, Winawer SJ. Screening colonoscopy. In: Colorectal cancer: a clinical guide to therapy. Edited by H Bleiberg, N Kemeny, P Rougier, and H Wilke. Martin Dunitz Ltd, London, 2002; pp 39-45.

  12. Winawer SJ, Zauber AG. The advanced adenoma as the primary target of screening. Gastrointestinal Endoscopy Clinics of North America 2002; 12:1-10. Review.

  13. Zauber AG, Vogelaar I, van Ballegooijen, Boer R, Loeve F, Habbema JDF, and Winawer SJ. A statistical model for post-polypectomy surveillance- a virtual alternative to virtual colonoscopy? Falk Symposium 149. Highlights in Gastrointestinal Oncology; edited by van Cutsem E, Rustgi AK, Schmiegel W, Zeitz M; Springer , The Netherlands, 2006: Springer, 2006: 111-128.

  14. Kudo S, Lambert R, Allen JI, Fujii H, Fujii T, Kashida H, Matsuda T, Mori M, Saito H, Shimoda T, Tanaka S, Watanabe H, Sung JJ, Feld AD, Inadomi JM, O’Brien MJ, Lieberman DA, Ransohoff DF, Soetikno RM, Triadafilopoulos G, Zauber AG, Teixeira CR, Rey JF, Jaramillo E, Rubio CA, Van Gossum A, Jung M, Vieth M, Jass JR, Hurlstone PD. Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc. 2008 Oct; 68(4 Suppl):S3-47. Review.

  15. van Ballegooijen M, Boer R, Zauber AG. Simulation of colorectal cancer screening: what we do and do not know and does it matter. Best Pract Res Clin Gastroenterol. 2010 Aug; 24(4):427-37.

  16. Zauber AG. Cost-effectiveness of colonoscopy. Gastrointest Endosc Clin N Am. 2010 Oct; 20(4):751-70.

EDITORIALS

  1. Winawer SJ, Zauber AG. Colorectal cancer screening: now is the time. CMAJ 2000; 163:543-544.

  2. Winawer SJ, Zauber AG. Colonoscopic polypectomy and the incidence of colorectal cancer. Gut 2001; 48:753-4.

  3. Zauber AG. Quality control for flexible sigmoidoscopy: which polyps count? Gastroenterology 2004; 126:1474-1477

  4. Bertagnolli MM, Zauber AG, Solomon S. Prostaglandin inhibition and cardiovascular risk: maybe timing really is everything. Cancer Prev Res (Phila) 2009; 2(3):195-6.

LETTERS TO THE EDITOR

  1. Winawer SJ, Zauber AG. Post-polypectomy surveillance. [Reply Letter] N Engl J Med 1993; 329:887-888

  2. Zauber AG, Bishop DT, Winawer SJ. Risk of colorectal cancer in families of patients with adenomatous polyps [Reply Letter]. N Eng J Med 1996; 334:1339-1340.

  3. Zauber AG, Winawer SJ, Stewart ET. Comparison of Colonoscopy and Double-Contrast Barium Enema. [Reply Letter] N Engl J Med 2000; 343:1729-30.

  4. Zauber AG, O’Brien MJ, Winawer SJ. On finding flat adenomas: is the search worth the gain? Gastroenterology 2002; 122:839-40.

  5. Zauber AG, Winawer SJ. High-quality colonoscopies must be an integral part of screening and surveillance programs. Gastroenterology 2006; 130:620-1.

  6. Rutter CM, Kuntz KM, Zauber AG; Colorectal Cancer Modeling Group in the Cancer Intervention and Surveillance Modeling Network. Extracolonic findings from CTC: balancing risks and benefits. AJR Am J Roentgenol 2009; 193(5):W470.

  7. Zauber AG, Lansdorp-Vogelaar I. Changes in risk factors and increases in screening contribute to the decline in colorectal cancer mortality, 1975 to 2000. Gastroenterology 2010; 139(2):698.

  8. Zauber AG, van Ballegooijen M, Petitti D, Lansdorp-Vogelaar I. United States Preventive Services Task Force recommendations: age to end screening misunderstood. Dis Colon Rectum 2010; 53(10):1453.

  9. Winawer SJ, Zauber AG. Incidence reduction following colonoscopic polypectomy. Am J Gastroenterol 2011; 106(2):370.

My Pages

My Projects